• Explore /
  • Poster
  • / Real-world outcomes of brentuximab vedotin maintenance after autologous stem cell transplant in relapsed/refractory classical Hodgkin lymphoma: Is less enough?

Real-world outcomes of brentuximab vedotin maintenance after autologous stem cell transplant in relapsed/refractory classical Hodgkin lymphoma: Is less enough?

Abstract Video & Slides Poster

Authors

null

Charlotte Burton Wagner

Huntsman Cancer Institute-University of Utah, Salt Lake City, UT

Charlotte Burton Wagner , Daniel Arthur Ermann , Kenneth M. Boucher , Adrienne Nedved , Ivana N. M. Micallef , Haris Hatic , Gaurav Goyal , Erin Hickey , Amanda Fegley , Courtney Samuels , Manali K. Kamdar , Sheeba Habeeb Ba Aqeel , Pallawi Torka , Kira MacDougall , Azra Borogovac , Sridevi Rajeeve , Kalub Fedak , Elizabeth Travers , Harsh Shah

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Hodgkin Lymphoma

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7514)

DOI

10.1200/JCO.2022.40.16_suppl.7514

Abstract #

7514

Poster Bd #

168

Abstract Disclosures

Similar Posters

Poster

2022 ASCO Annual Meeting

Outcomes of classic Hodgkin lymphoma, relapsed within one year of diagnosis, in the era of novel agents.

Outcomes of classic Hodgkin lymphoma, relapsed within one year of diagnosis, in the era of novel agents.

First Author: Sanjal Desai

First Author: Paul M. Barr

First Author: Federico Losco

First Author: Paul David Harker-Murray